\n<\/p>\n
\n\t\t\t\t\t\t\t\tFirst and only approved antibody-drug conjugate for FR\u03b1-positive platinum-resistant ovarian cancer demonstrates significant improvements in progression-free and overall survival, expanding targeted treatment options in Singapore.<\/p>\n
<\/p>\n
<\/p>\n
\n<\/ul>\n
AbbVie\u00a0 announced the availability of ELAHERE\u00ae (mirvetuximab soravtansine) in Singapore for the treatment of platinum-resistant high grade serous epithelial ovarian cancer, fallopian tube or primary peritoneal cancer.<\/span><\/p>\n ELAHERE is indicated as a monotherapy for the treatment of adult patients with folate receptor alpha (FR\u03b1) positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens.<\/span><\/p>\n “Patients with platinum-resistant ovarian cancer have historically had a poor prognosis with limited treatment options,” said Associate Professor David Tan, Senior Consultant, Department of Haematology-Oncology, National University Cancer Institute, Singapore (NCIS). “Depending on their clinical profile and prior treatments, the availability of a targeted therapy that can lead to improved survival outcome is certainly a welcome option for patients with FR\u03b1 positive ovarian cancer.”<\/span><\/p>\n “Biomarker testing, including for FR\u03b1 status, can help inform treatment decisions as targeted therapies become available for certain patient groups. In clinical practice, such testing may be performed at diagnosis or at the point of disease progression, depending on the patient’s condition and care plan,” he added.<\/span><\/p>\n Ovarian cancer is a malignant\u00a0tumour<\/span>\u00a0that arises from the ovaries and adjacent structures such as the fallopian tubes or peritoneum.[3]<\/sup>\u00a0It is known as the deadliest gynaecological cancer because it is usually detected in its later stages of development and spread.[4]<\/sup>\u00a0First-line treatment for advanced ovarian cancer typically consists of surgery and platinum-based chemotherapy,[5]<\/sup>\u00a0but 70% of patients experience recurrence after initial therapy, and resistance to platinum therapy accumulates with repeated treatments.[6]<\/sup>,<\/sup>[7]<\/sup>\u00a0As a result, about one in five patients relapse within six months of platinum therapy, progressing to platinum-resistant ovarian cancer (PROC).[<\/sup>5],<\/sup>[8]<\/sup>\u00a0These patients have limited treatment options,[9]<\/sup>\u00a0and many are physically frail from prior therapies.[10]<\/sup>\u00a0In addition to the physical burden, patients may experience emotional distress due to social isolation and side effects such as hair loss from prior treatments, which can negatively impact prognosis.[11],[12]<\/sup><\/span><\/p>\n In Singapore, ovarian cancer is the 6th most common cancer and the 6th most common cause of death from cancer in women (2019-2023).\u00a0The age-standardised incidence<\/span>\u00a0rate for ovarian cancer increased from 10.8 per 100,000 in 1998-2002 to 12.2 per 100,000 in 2019-2023. The five-year (2019-2023) age-standardised relative survival rate for ovarian cancer is 45.3%, much lower than other female cancers such as breast (84.2%), uterus (73.3%) and cervix (62.4%).[13]<\/sup><\/span><\/p>\n “Ovarian cancer can be devastating, taking women away from precious moments with their family, disrupting careers and the many other important contributions that women make to society.” said Rama V, ASEAN General Manager, AbbVie Pte Ltd. “The availability of ELAHERE provides a much needed clinically meaningful option for patients who receive the distressing news their ovarian cancer has returned, fearing what’s next in their treatment journey after they’ve developed platinum-resistance.”<\/span><\/p>\n “We are pleased that this availability brings the innovative therapeutic benefits of antibody-drug conjugate therapy to address a major unmet need for patients with platinum-resistant ovarian cancer. AbbVie is developing innovative approaches based on targeted therapy in ovarian cancer, a disease where early diagnosis and treatment remain difficult. And we will continue our efforts to improve treatment outcomes across all stages of ovarian cancer and to create a healthier tomorrow for women,” said Kenneth Sim, ASEAN Medical Director, AbbVie Pte Ltd.<\/span><\/p>\n In approximately one third of people living with ovarian cancer, the folate-receptor alpha (FR\u03b1) biomarker is highly expressed (\u226575% of\u00a0tumour<\/span>\u00a0cells with \u22652+ membrane staining intensity). To determine biomarker status, patients can be tested with Roche’s VENTANA\u00ae FOLR1 (FOLR1-2.1) RxDx Assay at diagnosis or at the first sign of resistance to platinum-based chemotherapy. AbbVie collaborated with Roche Diagnostics on the newly approved immunohistochemistry (IHC) companion diagnostic test to identify patients who may be eligible for ELAHERE.\u00a0<\/span><\/p>\n The marketing authorisation of ELAHERE is supported by data from MIRASOL: a global, Phase 3 open-label, randomised, controlled trial.<\/span><\/p>\n
<\/p>\n
<\/p>\n
<\/p>\n
\n<\/ul>\n \t\t\t\t<\/p>\n \t\t\t<\/div>\n First and only approved antibody-drug conjugate for FR\u03b1-positive platinum-resistant ovarian cancer demonstrates significant improvements in progression-free and overall survival, expanding targeted treatment options in Singapore….<\/p>\n","protected":false},"author":1,"featured_media":72768,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"fifu_image_url":"","fifu_image_alt":"","footnotes":""},"categories":[2611],"tags":[],"class_list":["post-72767","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-buzz-headlines","wpcat-2611-id"],"_links":{"self":[{"href":"https:\/\/sgbuzz.com\/index.php?rest_route=\/wp\/v2\/posts\/72767","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sgbuzz.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sgbuzz.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sgbuzz.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/sgbuzz.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=72767"}],"version-history":[{"count":0,"href":"https:\/\/sgbuzz.com\/index.php?rest_route=\/wp\/v2\/posts\/72767\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/sgbuzz.com\/index.php?rest_route=\/wp\/v2\/media\/72768"}],"wp:attachment":[{"href":"https:\/\/sgbuzz.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=72767"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sgbuzz.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=72767"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sgbuzz.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=72767"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
<\/p>\n
\n
\n
Read Full Article At Source <\/a>
\n